Continuous Glucose Monitoring for Type 1 Diabetes

Overseen By Guillermo Umpierrez, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Emory University

Must be taking: Insulin

Must not be taking: Immunosuppressive agents

Disqualifiers: ICU, Type 2 diabetes, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: Up to 10 days

100 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether the Dexcom G7 Continuous Glucose Monitor (CGM) manages blood sugar levels more effectively than the usual finger-prick test for people with Type 1 Diabetes in the hospital. Researchers aim to determine if the CGM can maintain blood sugar within the target range and reduce episodes of low blood sugar. Participants will be divided into two groups: one using the CGM and the other using the standard finger-prick method. This trial suits those with Type 1 Diabetes who have struggled to control their blood sugar levels and are hospitalized for at least three days. As an unphased trial, it offers a unique opportunity to explore innovative diabetes management strategies.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does require that you are treated with insulin therapy. It might be best to discuss your specific medications with the trial coordinators.

What prior data suggests that the Dexcom G7 Continuous Glucose Monitoring is safe for use in Type 1 Diabetes patients?

Research has shown that the Dexcom G7 Continuous Glucose Monitor (CGM) is accurate and safe for people with diabetes. In one study, participants used the Dexcom G7 for over 10 days, and it provided reliable blood sugar readings without major issues. Another study focused on pregnant individuals with diabetes and confirmed the device's safety and accuracy throughout pregnancy.

The device continuously tracks blood sugar levels, helping to reduce the risk of very low or very high blood sugar. Overall, the Dexcom G7 has been well-received, with no significant safety concerns reported, making it a promising option for effective blood sugar management. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Unlike the standard of care for managing type 1 diabetes, which often involves periodic point-of-care (POC) glucose testing and insulin adjustments, the Dexcom G7 Continuous Glucose Monitor (CGM) offers a real-time, dynamic approach. This wearable device provides continuous glucose readings, allowing for more precise insulin therapy based on detailed glucose trends rather than sporadic checks. Researchers are excited about the Dexcom G7 because it can potentially improve glucose control by identifying glycemic excursions and preventing severe hyperglycemia more effectively. This real-time monitoring could lead to better overall diabetes management and improved patient outcomes.

What evidence suggests that the Dexcom G7 CGM is effective for glycemic control in Type 1 Diabetes?

Studies have shown that the Dexcom G7 Continuous Glucose Monitoring (CGM) system can significantly aid people with Type 1 Diabetes in managing their blood sugar levels. Specifically, users of the Dexcom CGM spend more time with their blood sugar in the healthy range of 70-180 mg/dl. Research also indicates that these users experience fewer instances of both low and high blood sugar. One study found that users reduced their A1C levels, a measure of long-term blood sugar control, by an average of 1%. This trial will compare the Dexcom G7 CGM system with standard glucose monitoring. Evidence suggests that the Dexcom G7 effectively helps people with Type 1 Diabetes maintain better blood sugar control. ^{1 3 4 6 7}

Who Is on the Research Team?

Guillermo Umpierrez, MD

Principal Investigator

Emory University

Are You a Good Fit for This Trial?

This trial is for people with poorly controlled Type 1 Diabetes Mellitus. Participants should be hospitalized or recently discharged and need to manage their blood sugar levels. Specific criteria for joining or reasons you can't join are not provided here.

Inclusion Criteria

Expected length of hospital stay > three days at the time of randomization

I have Type 1 Diabetes and am on insulin therapy.

I was diagnosed with Type 1 Diabetes and have high blood sugar or HbA1c over 7%.

Exclusion Criteria

Patients expected to require MRI procedures during hospitalization

Subjects using CGM technology before admission

I am currently admitted to the ICU.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants are hospitalized and receive either POC testing or Dexcom G7 CGM for glucose monitoring and insulin therapy adjustment

Up to 10 days

Daily monitoring during hospitalization

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Dexcom G7

Trial Overview

The study compares two ways of monitoring blood sugar: the Dexcom G7 Continuous Glucose Monitoring (CGM) system versus traditional fingerstick tests that measure at specific times (POC). It looks at how well each method keeps blood sugar within a safe range and prevents low blood sugar episodes in the hospital.

How Is the Trial Designed?

Group I: Dexcom CGM Experimental Treatment 1 Intervention

Severe hyperglycemia will be managed by primary care professionals (Hospitalist Service) intravenously with subcutaneous insulin therapy. Subjects will be invited to participate in the study after the resolution of severe hyperglycemia (BG \< 400 mg/dl). Subjects will wear a real-time Dexcom G7 CGM for up to 10 days. Insulin therapy will be titrated based on daily CGM reports, including mean glucose, glycemic excursions, hypoglycemia, and severe hyperglycemia \> 180 and \>250 mg/dl values. Participants will wear a Dexcom rtCGM for up to 10 days during hospitalization.

Group II: Standard of Care Active Control 1 Intervention

Severe hyperglycemia will be managed by primary care professionals (Hospitalist Service) with intravenous or subcutaneous insulin therapy. Subjects will be invited to participate in the study after the resolution of severe hyperglycemia (BG \< 400 mg/dl). Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded to the electronic medical record (EMR) system. The research team, together with the Primary care (PCP) team, will adjust daily insulin orders based on POC readings (standard of care). In addition, subjects will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, medicine, or research teams) during hospitalization for up to 10 days.

Who Is Running the Clinical Trial?

Emory University

Lead Sponsor

Trials

1,735

Recruited

2,605,000+

DexCom, Inc.

Industry Sponsor

Trials

151

Recruited

35,700+

Kevin Sayer

DexCom, Inc.

Chief Executive Officer since 2015

Bachelor’s and Master’s degrees in Accounting and Information Systems from Brigham Young University

Dr. Shelly Lane

DexCom, Inc.

Chief Medical Officer since 2023

MD from University of California, San Diego

Published Research Related to This Trial

In a real-world setting, the blinded Dexcom G6 Pro continuous glucose monitor (CGM) demonstrated a mean absolute relative difference (MARD) of 11.0% over a median wear time of 50 hours, indicating reliable accuracy for glucose monitoring in individuals with type 1 diabetes.

The accuracy of the Dexcom G6 Pro improved after the first 12 hours of use, stabilizing at around 10.1% MARD thereafter, which aligns with previous laboratory-based accuracy findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Testing the Real-World Accuracy of the Dexcom G6 Pro CGM During the Insulin-Only Bionic Pancreas Pivotal Trial. Marak, MC., Calhoun, P., Damiano, ER., et al.[2023]

In a study involving 11 patients with type 1 diabetes, the Dexcom G5 Mobile (DG5) continuous glucose monitor demonstrated significantly better accuracy than the Eversense (EVS) implantable sensor during controlled clinical conditions, particularly when blood glucose levels were decreasing.

While both devices showed similar accuracy during home monitoring, DG5 had a lower median absolute relative difference (ARD) of 7.91% compared to EVS's 11.4% during glucose excursions in a clinical setting, indicating it may be more reliable for detecting rapid changes in glucose levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparing the accuracy of transcutaneous sensor and 90-day implantable glucose sensor. Boscari, F., Vettoretti, M., Amato, AML., et al.[2021]

Continuous glucose monitoring (CGM) is becoming a standard tool for managing type 1 diabetes, with advancements that may lead to its integration into closed-loop artificial beta-cell systems.

The review highlights the accuracy and performance of the two currently approved CGM devices, discussing their clinical trial results, limitations, and best practices for use in diabetes care.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Continuous glucose monitoring in type 1 diabetes. Weinzimer, SA., Tamborlane, WV., Chase, HP., et al.[2019]

Continuous glucose monitors (CGMs) have been associated with over 25,000 complaints of sensor inaccuracy reported to the FDA since 2015, highlighting significant safety concerns regarding their reliability for insulin dosing.

Despite evidence of sporadic and unpredictable errors in CGMs, the FDA approved the Dexcom G5 for nonadjunctive use, indicating a need for improved safety procedures rather than removing existing safeguards.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe? Shapiro, AR.[2018]

The Dexcom G6 continuous glucose monitoring (CGM) system demonstrated a mean absolute relative difference (MARD) of 7.7% in accuracy when compared to laboratory blood glucose measurements, indicating high reliability for monitoring glucose levels in children and adolescents with type 1 diabetes.

With 96.2% of estimated glucose values falling within 20% of the reference values, the G6 system's accuracy supports its potential to enhance glycemic control and encourage consistent use among young patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Performance of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System in Pediatric Participants With Type 1 Diabetes. Welsh, JB., Zhang, X., Puhr, SA., et al.[2020]

The seventh generation (G7) Dexcom continuous glucose monitor (CGM) demonstrated high accuracy in glucose readings, with mean absolute relative differences (MARD) of 8.2% for arm sensors and 9.1% for abdomen sensors, based on data from 316 participants over 10.5 days.

No serious adverse events were reported during the study, indicating that the G7 CGM is safe for use in adults with diabetes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Garg, SK., Kipnes, M., Castorino, K., et al.[2022]

The SEVEN PLUS System, a new continuous glucose monitoring device, demonstrated a median absolute relative difference of 13.0% compared to laboratory reference measurements, indicating good accuracy in glucose tracking for the 53 participants, mostly with type 1 diabetes.

The device showed improved sensor life, with 89% of sensors lasting the full 7 days, and no serious adverse events were reported, highlighting its safety and reliability for users.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New features and performance of a next-generation SEVEN-day continuous glucose monitoring system with short lag time. Bailey, T., Zisser, H., Chang, A.[2009]

The Eversense continuous glucose monitoring (CGM) system demonstrated long-term safety with no related serious adverse events reported among 3023 patients over multiple sensor insertion-removal cycles, totaling 1260 patient-years of follow-up.

The most common minor adverse events included site infections and irritation, but these occurred at low rates, indicating that the Eversense CGM system is generally well-tolerated in real-world settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Deiss, D., Irace, C., Carlson, G., et al.[2020]

The analysis of adverse events for the Medtronic 670G insulin pump revealed that users experienced more hypoglycemic events when the auto mode was activated compared to when it was turned off.

For the Dexcom continuous glucose monitors, complaints about inaccuracies were most common when the readings fell within the acceptable range (B zone), indicating potential confusion among users regarding the reliability of the device.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An Analysis of 2019 FDA Adverse Events for Two Insulin Pumps and Two Continuous Glucose Monitors. Krouwer, JS.[2022]

The Guardian™ continuous glucose monitoring (CGM) system showed good accuracy in measuring glucose levels in children and adolescents with type 1 diabetes, with a mean absolute relative difference of about 10.9% for the Guardian Connect system and 11.1% for the Glucose Sensor Recorder.

The system was safe, with only one minor adverse event reported (contact dermatitis) and no serious device-related complications, supporting its use for diabetes management in pediatric patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes. Slover, RH., Tryggestad, JB., DiMeglio, LA., et al.[2018]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9208857/

Accuracy and Safety of Dexcom G7 Continuous Glucose ...

We evaluated the accuracy and safety of a seventh generation (G7) Dexcom continuous glucose monitor (CGM) during 10.5 days of use in adults with diabetes.

2.

provider.dexcom.com

provider.dexcom.com/G7/t1-diabetes

CGM for Type 1 Diabetes Patients

Dexcom CGM was clinically proven to increase TIR 1,4,5 less frequent hypo- and hyperglycemic events. T1D users at high hypoglycemia risk experienced a 72% ...

3.

onlinelibrary.wiley.com

onlinelibrary.wiley.com/doi/10.1111/dme.15519

Clinical outcomes of a real‐world prospective study using ...

This study assessed real-world glycaemic outcomes associated with the use of Dexcom ONE in adults with suboptimally controlled diabetes.

4.

diabetesjournals.org

diabetesjournals.org/clinical/article/42/4/540/157065/The-Dexcom-Community-Glucose-Monitoring-Project-6

The Dexcom Community Glucose Monitoring Project: 6-Month ...

After 6 months of program participation, mean A1C decreased by 2.4 ± 1.9% from baseline to 6-month follow-up (from 9.4 ± 1.7 to 7.1 ± 1.2%, P <0.001).

5.

provider.dexcom.com

provider.dexcom.com/diamond-randomized-controlled-trial-examining-benefit-cgm-use-adults-type-1-diabetes-insulin

Clinical Evidence - Dexcom CGM Improves Glucose Control

Dexcom CGM use resulted in a significant A1C reduction in patients with T1D on insulin injections. In study participants using Dexcom CGM: Overall: an average 1 ...

6.

ca.provider.dexcom.com

ca.provider.dexcom.com/articles/new-study-concludes-dexcom-g7-accurate-and-safe-during-pregnancies-complicated-diabetes

New Study Concludes Dexcom G7 is “Accurate and Safe ...

The researchers concluded that Dexcom G7 provides accurate readings across all gestational ages in pregnant individuals with T1D, T2D, or GDM.

7.

clinicaltrials.gov

clinicaltrials.gov/study/NCT04794478

Study Details | NCT04794478 | Evaluation of the Safety ...

The objective of this study is to establish performance of the Dexcom CGM System (System) in comparison to a blood glucose comparator method. Official Title.